The Supreme Court ruled today that human genes can’t be patented, marking a victory for women at risk of breast and ovarian cancer and doctors and geneticists who argued that the patents would disrupt important biotechnology research.
The ruling stemmed from a Utah company, Myriad Genetics, which held an exclusive patent on the genes, BRCA1 and BRCA2, that indicate whether a woman was at a higher risk for developing breast or ovarian cancer.
The court said that products of nature like genes, unlike invented products, are not eligible for patents. Read more at The Wall Street Journal.
{Andy Heller-Matzav.com Newscenter}
